『Medical History Mysteries』のカバーアート

Medical History Mysteries

Medical History Mysteries

著者： Creator at Obomedia
無料で聴く

Ever wondered about the strange cures, bizarre medical practices, and forgotten pioneers that shaped modern healthcare? Medical History Mysteries unearths the most compelling stories from the annals of medicine.

Join us as we explore the captivating and often unsettling evolution of medical science. From ancient remedies and medieval plagues to groundbreaking surgical feats and ethical dilemmas, we dissect the fascinating intersection of human ingenuity, suffering, and discovery. Each episode brings to life historical medical cases, scientific breakthroughs, and the enduring human quest to understand and conquer disease.

New episodes arrive daily, Monday through Sunday, at 7:00 PM EST, offering a fresh dose of historical intrigue and medical insights. We delve deep into specific events, figures, and concepts, ensuring a thorough and engaging exploration of each topic. Expect well-researched narratives that are both informative and thought-provoking.

This podcast is for anyone fascinated by the history of medicine, the human body, and the incredible journey of scientific progress. If you love historical podcasts and uncovering the truth behind medical myths, you’ve found your next obsession.

Subscribe now to unravel the past with Medical History Mysteries.© 2026 OBOMEDIA Creators ノンフィクション犯罪
エピソード
  • Midnight Drop: How a $16M Alzheimer's Miracle Vanished

    Midnight Drop: How a $16M Alzheimer's Miracle Vanished
    2026/07/24
    Midnight Drop: How a $16M Alzheimer's Miracle Vanished

    Hope turned to doubt overnight: a $16 million NIH grant, hundreds of patients in trials, and a drug called simufilam that rested on a disputed protein called filamin A - then every criminal charge was dropped at midnight. What happened to the biomarker data, the images that triggered retractions, and the independent verification that never arrived?

    In this episode, we lay out the timeline from the 2012 Journal of Neuroscience paper that introduced PTI-125 to the 2025 courtroom where charges were dismissed, tracing the grant, the clinical trials, the failed and later conflicting biomarker results, and the unresolved scientific record. How did foundational research, public funding, and patient trials converge - and vanish - without a clear resolution?

    Person: Hoau-Yan Wang
    Person: Lindsay Burns
    Event: Retraction of foundational opioid-related FLNA papers in 2022
    Date: Phase IIb failed biomarker analysis in May 2020
    Amount: $16,000,000 federal grant from NIH

    - 2012: PTI-125 (later renamed simufilam) first described in the Journal of Neuroscience.
    - 2017: Mouse data supporting the mechanism published in Neurobiology of Aging.
    - 2018: National Institutes of Health awarded Cassava Sciences $16,000,000 to support early clinical trials.
    - May 2020: Cassava's Phase IIb cerebrospinal fluid biomarker analysis initially failed to show the expected biological signal.
    - 2022: Foundational FLNA opioid-related papers by Wang and Maya Frankfurt were retracted due to similarities in background pixels in western blot images.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    22 分
  • The Protein That Promised a Cure - and Vanished from the Data

    The Protein That Promised a Cure - and Vanished from the Data
    2026/07/24
    The Protein That Promised a Cure - and Vanished from the Data

    Hope turned to doubt when pixel-for-pixel repeats in lab images and a single lab's dominance over the evidence underpinned a drug that enrolled over 400 people with Alzheimer's - so what happened to the missing verification that should have stopped human trials? Who knew about the data shifts, and why did a failed biomarker readout get reversed months later?

    In this episode, we follow the path from a scaffolding protein called filamin A to a compound taken into human trials, tracing publications, funding, and the contested biomarker results to ask whether the scientific basis for simufilam was ever independently confirmed.

    Person: Hoau-Yan Wang
    Person: Lindsay Burns
    Company: Cassava Sciences (formerly Pain Therapeutics)
    Drug: simufilam (PTI-125)
    Enrollment: more than 400 people by August 2022

    - In 2012 Wang and Burns published a key paper linking filamin A to Alzheimer's in the Journal of Neuroscience.
    - In 2017 a follow-up study in Neurobiology of Aging reported that PTI-125 improved pathology in transgenic Alzheimer's-model mice.
    - In 2018 the NIH awarded funding to Cassava Sciences for early human trials of simufilam.
    - By March 2020 open-label human studies had begun with blood biomarker measurements taken from enrolled patients.
    - In May 2020 a Phase IIb biomarker analysis failed to support the hypothesized effects, but in September 2020 Cassava announced that an outside lab had produced improved biomarker results.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    23 分
  • The Case of the Vanishing Blots: How Simufilam's Evidence Disappeared

    The Case of the Vanishing Blots: How Simufilam's Evidence Disappeared
    2026/07/24
    The Case of the Vanishing Blots: How Simufilam's Evidence Disappeared

    A single set of laboratory photographs - western blots - became the fulcrum of a dispute that touched federal grand juries, NIH funding, and hundreds of Alzheimer’s patients. Pixels matching across images from supposedly separate experiments, an outside lab that turned out to be the same academic group behind the drug, and a night-before-trial DOJ decision leave one central question: how did the visual evidence underpinning simufilam vanish into ambiguity?

    In this episode, we trace the chronology of simufilam’s rise and the contested data that sustained it, laying out the key players, the published papers, and the discovery that blurred the line between independent confirmation and internal reanalysis. What does the record show about the provenance of the western blots, and why did four federal investigations still not resolve that question?

    Person: Hoau-Yan Wang
    Person: Lindsay Burns
    Person: Thomas Südhof
    Date: September 2020
    Event: Re-analysis of biomarker data presented as from an outside laboratory

    - Cassava Sciences announced an outside laboratory confirmed simufilam’s biomarker improvements in September 2020.
    - The “outside laboratory” that re-analyzed the failed May 2020 cerebrospinal fluid biomarkers was Wang’s CUNY lab.
    - Simufilam (PTI-125) was built on findings about filamin A (FLNA) reported in PLOS One papers co-authored by Wang, Burns, and Maya Frankfurt.
    - NIH funding was awarded in 2018 and open-label studies began in March 2020 for simufilam.
    - Four simultaneous federal investigations occurred and the original laboratory data was never produced, leaving no court-established guilt or institutional proof of misconduct.

    To listen to this podcast ad-free and access premium episodes, try our subscription with a 14-day free trial at obomedia.com.

    © 2026 OBOMEDIA. All rights reserved.
    This episode and its content (audio, text, and related materials) are the exclusive property of OBOMEDIA and are protected by applicable copyright laws. Reproduction, distribution, editing, or commercial use, in whole or in part, without prior written permission from OBOMEDIA is prohibited. For permissions, licensing, and business inquiries: business@obomedia.com.
    続きを読む 一部表示
    23 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません